Your browser doesn't support javascript.
loading
Testosterone therapy to prevent type 2 diabetes mellitus in at-risk men (T4DM): Design and implementation of a double-blind randomized controlled trial.
Wittert, Gary; Atlantis, Evan; Allan, Carolyn; Bracken, Karen; Conway, Ann; Daniel, Mark; Gebski, Val; Grossmann, Mathis; Hague, Wendy; Handelsman, David J; Inder, Warrick; Jenkins, Alicia; Keech, Anthony; McLachlan, Robert; Robledo, Kristy; Stuckey, Bronwyn; Yeap, Bu B.
Afiliação
  • Wittert G; Freemasons Foundation Centre for Mens Health, School of Medicine, University of Adelaide, Adelaide, South Australia, Australia.
  • Atlantis E; Freemasons Foundation Centre for Mens Health, School of Medicine, University of Adelaide, Adelaide, South Australia, Australia.
  • Allan C; School of Nursing and Midwifery, Western Sydney University, Penrith, Australia.
  • Bracken K; Department of Clinical Research, Hudson Institute of Medical Research, Melbourne, Australia.
  • Conway A; NHMRC Clinical Trials Centre, University of Sydney, Camperdown, Australia.
  • Daniel M; Anzac Research Institute and Andrology Department, Concord Hospital, Sydney, New South Wales, Australia.
  • Gebski V; Health Research Institute, University of Canberra, Australian Capital Territory, Australia.
  • Grossmann M; NHMRC Clinical Trials Centre, University of Sydney, Camperdown, Australia.
  • Hague W; Dept. of Medicine, The Austin Hospital and University of Melbourne, Victoria, Australia.
  • Handelsman DJ; NHMRC Clinical Trials Centre, University of Sydney, Camperdown, Australia.
  • Inder W; Anzac Research Institute and Andrology Department, Concord Hospital, Sydney, New South Wales, Australia.
  • Jenkins A; Department of Diabetes and Endocrinology, Princess Alexandra Hospital and University of Queensland, Woolloongabba, Australia.
  • Keech A; NHMRC Clinical Trials Centre, University of Sydney, Camperdown, Australia.
  • McLachlan R; NHMRC Clinical Trials Centre, University of Sydney, Camperdown, Australia.
  • Robledo K; Department of Clinical Research, Hudson Institute of Medical Research, Melbourne, Australia.
  • Stuckey B; NHMRC Clinical Trials Centre, University of Sydney, Camperdown, Australia.
  • Yeap BB; Keogh Institute for Medical Research, Department of Endocrinology and Diabetes, Sir Charles Gairdner Hospital, Nedlands, Western Australia, and Medical School, University of Western Australia, Perth, Western Australia.
Diabetes Obes Metab ; 21(4): 772-780, 2019 04.
Article em En | MEDLINE | ID: mdl-30520208
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Testosterona / Intolerância à Glucose / Diabetes Mellitus Tipo 2 / Programas de Redução de Peso / Androgênios / Obesidade Idioma: En Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Testosterona / Intolerância à Glucose / Diabetes Mellitus Tipo 2 / Programas de Redução de Peso / Androgênios / Obesidade Idioma: En Ano de publicação: 2019 Tipo de documento: Article